LLY vs. ABBV

Last updated Jun 3, 2026

LLY (Eli Lilly and Company) and ABBV (AbbVie Inc.) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, LLY returned 32.48%/yr vs 17.47%/yr for ABBV. At a 0.41 correlation, their price movements are largely independent.

Performance

LLY vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eli Lilly and Company (LLY) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LLY achieves a -0.64% return, which is significantly higher than ABBV's -4.18% return. Over the past 10 years, LLY has outperformed ABBV with an annualized return of 32.48%, while ABBV has yielded a comparatively lower 17.47% annualized return.

LLY

• 1D: -1.67%
• 1M: 10.66%
• YTD: -0.64%
• 6M: 2.07%
• 1Y: 43.44%
• 3Y*: 34.95%
• 5Y*: 40.65%
• 10Y*: 32.48%

ABBV

• 1D: 1.16%
• 1M: 4.26%
• YTD: -4.18%
• 6M: -2.42%
• 1Y: 18.95%
• 3Y*: 20.56%
• 5Y*: 18.28%
• 10Y*: 17.47%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LLY vs. ABBV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LLY Eli Lilly and Company	-0.64%	40.25%	33.30%	60.91%	34.26%	66.08%	31.04%	16.14%	40.45%	17.83%
ABBV AbbVie Inc.	-4.18%	33.08%	18.86%	-0.23%	24.01%	32.43%	27.72%	1.47%	-0.96%	60.07%

Correlation

The correlation between LLY and ABBV is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.30
Correlation (5Y) Calculated over the trailing 5-year period	0.36
Correlation (10Y) Calculated over the trailing 10-year period	0.41
Correlation (All Time) Calculated using the full available price history since Jan 3, 2013	0.41

The correlation between LLY and ABBV shifts across timeframes, from 0.30 (3 years) to 0.41 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap LLY : $953.37B ABBV : $382.12B
EPS LLY : $28.14 ABBV : $2.05
PE Ratio LLY : 37.81 ABBV : 104.95
PS Ratio LLY : 13.23 ABBV : 6.08
PB Ratio LLY : 30.56 ABBV : 13.90
Total Revenue (TTM) LLY : $72.25B ABBV : $62.82B
Gross Profit (TTM) LLY : $59.75B ABBV : $46.15B
EBITDA (TTM) LLY : $32.97B ABBV : $17.96B

Return for Risk

LLY vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LLY

LLY Risk / Return Rank: 72
LLY Sharpe Ratio Rank: 75
LLY Sortino Ratio Rank: 69
LLY Omega Ratio Rank: 70
LLY Calmar Ratio Rank: 73
LLY Martin Ratio Rank: 74

ABBV

ABBV Risk / Return Rank: 62
ABBV Sharpe Ratio Rank: 66
ABBV Sortino Ratio Rank: 59
ABBV Omega Ratio Rank: 58
ABBV Calmar Ratio Rank: 63
ABBV Martin Ratio Rank: 63

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LLY vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LLY	ABBV	Difference
Sharpe ratio Return per unit of total volatility	1.15	0.79	+0.36
Sortino ratio Return per unit of downside risk	1.71	1.25	+0.46
Omega ratio Gain probability vs. loss probability	1.23	1.16	+0.07
Calmar ratio Return relative to maximum drawdown	1.92	1.13	+0.79
Martin ratio Return relative to average drawdown	4.78	2.54	+2.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LLY vs. ABBV - Sharpe Ratio Comparison

The current LLY Sharpe Ratio is 1.15, which is higher than the ABBV Sharpe Ratio of 0.79. The chart below compares the historical Sharpe Ratios of LLY and ABBV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	LLY	ABBV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.15	0.79	+0.36
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	1.25	0.80	+0.44
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	1.08	0.68	+0.40
Sharpe Ratio (All Time) Calculated using the full available price history	0.57	0.73	-0.16

Drawdowns

LLY vs. ABBV - Drawdown Comparison

The maximum LLY drawdown since its inception was -68.24%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for LLY and ABBV.

Drawdown Indicators

	LLY	ABBV	Difference
Max Drawdown Largest peak-to-trough decline	-68.24%	-45.09%	-23.15%
Max Drawdown (1Y) Largest decline over 1 year	-23.64%	-17.32%	-6.32%
Max Drawdown (3Y) Largest decline over 3 years	-34.48%	-20.74%	-13.74%
Max Drawdown (5Y) Largest decline over 5 years	-34.48%	-21.92%	-12.56%
Max Drawdown (10Y) Largest decline over 10 years	-34.48%	-45.09%	+10.61%
Current Drawdown Current decline from peak	-5.56%	-9.77%	+4.21%
Average Drawdown Average peak-to-trough decline	-19.22%	-10.73%	-8.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.48%	7.67%	+1.81%

Volatility

LLY vs. ABBV - Volatility Comparison

Eli Lilly and Company (LLY) has a higher volatility of 9.11% compared to AbbVie Inc. (ABBV) at 5.42%. This indicates that LLY's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LLY	ABBV	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.11%	5.42%	+3.69%
Volatility (6M) Calculated over the trailing 6-month period	26.83%	17.63%	+9.20%
Volatility (1Y) Calculated over the trailing 1-year period	37.88%	23.95%	+13.93%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.79%	22.84%	+9.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	30.15%	25.74%	+4.41%

Dividends

LLY vs. ABBV - Dividend Comparison

LLY's dividend yield for the trailing twelve months is around 0.61%, less than ABBV's 3.13% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ABBV AbbVie Inc.	3.13%	2.87%	3.49%	3.82%	3.49%	3.84%	4.41%	4.83%	3.89%	2.65%	3.64%	3.41%
LLY Eli Lilly and Company	0.61%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Financials

LLY vs. ABBV - Profitability Comparison

The chart below illustrates the profitability comparison between Eli Lilly and Company and AbbVie Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.

Frequently Asked Questions

Can I hold both LLY and ABBV in my portfolio?

LLY and ABBV have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LLY or ABBV?

LLY has higher volatility (9.11%) compared to ABBV (5.42%). In terms of maximum drawdown, LLY dropped -68.24% vs ABBV's -45.09%.

Which has better risk-adjusted returns?

LLY currently has the higher Sharpe Ratio (1.15 vs 0.79), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.